Sobi posts continued solid progress for 1st-qtr
Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, today released financial results for the first quarter of 2023, showing that total revenues were up 6% year-on-year at 5,239 million Swedish kronor ($508.6 million), but down 2% at constant exchange rates (CER).
Earnings before interest, taxes, and amortization (EBITA) came in at 2,121 million kronor, up 64%, with an EBITA margin of 40%. Earnings per share (EPS) before dilution 3.60 kronor, +96%, and EPS adjusted before dilution was 3.60 kronor (3.67).
Sobi said that the full-year outlook for 2023 is unchanged. Revenue is anticipated to grow by a low-to-mid single-digit percentage at CER and EBITA margin adjusted is anticipated to be at a low 30s percentage of revenue. Sobi’s shares were down 2.7% at 254.80 kronor by mid-afternoon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze